Forge Therapeutics acquired spinoff Blacksmith Medicines while solar film producer Sinopont raised $145m in series D funding.
M&A
Antibiotic drug provider Forge Therapeutics has agreed to pay an undisclosed amount to acquire Blacksmith Medicines, a US-based inflammatory diseases therapy developer spun off by the corporate in early 2021. It had received an undisclosed amount of seed financing from investors including pharmaceutical companies Eli Lilly and Evotec as well as Alexandria Venture Investments, a subsidiary of life sciences real estate investment trust…
